Ajanta Pharma Limited, headquartered in India, is a prominent player in the pharmaceutical industry, specialising in the development and manufacturing of a diverse range of formulations. Founded in 1973, the company has established a strong presence in various operational regions, including Asia, Africa, and the Middle East. Ajanta Pharma is renowned for its focus on therapeutic areas such as ophthalmology, dermatology, and pain management, offering unique products that cater to specific medical needs. With a commitment to quality and innovation, the company has achieved significant milestones, including numerous approvals from regulatory authorities worldwide. Recognised for its robust market position, Ajanta Pharma continues to expand its global footprint, driven by a dedication to enhancing patient care through effective and affordable healthcare solutions.
How does Ajanta Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Ajanta Pharma's score of 26 is lower than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Ajanta Pharma reported total carbon emissions of approximately 46,999,960 kg CO2e, comprising 6,390,220 kg CO2e from Scope 1 and 40,007,740 kg CO2e from Scope 2 emissions. This represents a significant increase from 2023, where emissions were about 56,132,000 kg CO2e, with 4,368,550 kg CO2e from Scope 1 and 51,847,350 kg CO2e from Scope 2. Over the past few years, Ajanta Pharma has shown a trend of fluctuating emissions, with 2022 emissions recorded at approximately 51,443,670 kg CO2e, including 4,611,220 kg CO2e from Scope 1 and 46,633,150 kg CO2e from Scope 2. In 2021, the company emitted about 45,157,660 kg CO2e, with 3,660,360 kg CO2e from Scope 1 and 41,756,300 kg CO2e from Scope 2. Despite these figures, Ajanta Pharma has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon footprint. The company has not reported any Scope 3 emissions, indicating a focus primarily on direct and indirect emissions from their operations. Ajanta Pharma's commitment to addressing climate change remains unclear, as there are no documented climate pledges or reduction targets available. The pharmaceutical industry is increasingly under pressure to enhance sustainability practices, and Ajanta Pharma's future strategies will be crucial in aligning with global climate goals.
Access structured emissions data, company-specific emission factors, and source documents
2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|
Scope 1 | 3,660,360 | 0,000,000 | 0,000,000 | 0,000,000 |
Scope 2 | 41,756,300 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | - | - | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ajanta Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.